Advertisement


Joannie M. Ivory, MD, MSPH, on Increasing Participation of Black Patients With Cancer in Clinical Trials

2022 ASCO Quality Care Symposium

Advertisement

Joannie M. Ivory, MD, MSPH, of The University of North Carolina at Chapel Hill, discusses ways to raise the number of Black patients with cancer who take part in clinical trials. More successful accrual may be linked to conducting trials where Black patients live and designing studies to recruit a concrete target percentage of marginalized populations.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
One of the problems that we have in a medical community is the accrual of racial and ethnic minority. Participation in clinical trials has been an ongoing challenge, despite multiple efforts dating back to 1993 with the NIH Revitalization Act. So as part of our clinical trial called GETSET, which is under Alliance Research Cooperative Groups, we decided to take a look at the enrollment patterns as well as site level predictors to see if it's related to black participant recruitment. Now, under alliance, there are four membership types. There's the academic sites, there's the main member sites, and one is accruing versus non-accruing. And then there's also NCORP sites, which means NCI Community Oncology Research Program sites. So when we look at the accrual trajectories, what we saw was that for the first few months, no black participants were accrued compared to our non-black participants, where only the first two months there were no one accrued. But then there was a sharp increase in the rate of accrual compared to our black participants. And so we also looked at site level predictors, and the two statistically significant predictors were geographic region as well as the neighborhood racial composition. And so what we saw was that for geographic region, there was a higher proportion of black participants accrued to our study in the south regions as well as the northeast. And then when it came to neighborhood racial composition, what we saw was that the higher the proportion of blacks in the neighborhood, the higher proportion of black participants that were accrued to our study. Now, surprisingly, when we looked at the alliance membership types, like I mentioned earlier, the NCORP sites actually had not accrued many black participants at all. But a limitation was the small sample size. So we will plan to repeat our analysis once we reach full enrollment. So some of the key findings we saw was that if we put our clinical trials that are part of a research cooperative group in neighborhoods where black participants live, then we are more likely to accrue black participants. In addition, when it came to our NCORP sites, there were a small number of black participants accrue, but this might be due to site level predictors that we did not measure. However, we will do so at full enrollment. One thing for us to keep in mind is that when we actually want to target increase in enrollment of racial and minority participants in our clinical trial, it has to start with us. It has to start with the study design, and we can't be afraid to set targeted percentage of accrual of these populations. In addition, I think, we also have to continue work because we know that there are also barriers at multiple levels that we can address going further.

Related Videos

Symptom Management
Issues in Oncology

Dawn L. Hershman, MD, on Prophylactic Colony Stimulating Factors for Neutropenia: Improving Clinicians’ Prescribing Practices

Dawn L. Hershman, MD, of Columbia University College of Physicians and Surgeons, discusses findings that showed substantial variability in clinicians’ adherence to prescribing primary prophylactic colony stimulating factors in a pragmatic trial. Although the ability to opt out of the intervention is a feature of pragmatic trials, careful prestudy planning to estimate nonadherence is critical to ensure adequate power to detect an effect. Understanding reasons for intervention opt-outs may also inform future pragmatic studies aimed at improving adherence to practice guidelines.

Colorectal Cancer

S.M. Qasim Hussaini, MD, on Colon Cancer Treatment Outcomes and Historical Housing Discrimination

S. M. Qasim Hussaini, MD, of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, discusses findings from a nationwide study of the association between living in areas with discriminatory mortgage practices from the 1930s with present-day access to quality colon cancer care. The study underscores the importance of state- and federal-level practices on mortgage lending regulation and fair housing practices in determining equitable cancer risk, access to care, and outcomes (Abstract 69).

Legislation
Health-Care Policy

Justin M. Barnes, MD, on Medicaid Expansion and Changes in Cancer Mortality Rates

Justin M. Barnes, MD, of the Washington University School of Medicine, discusses the ways in which Medicaid expansion under the Affordable Care Act seems to affect distant diagnoses and cancer deaths per year, the differences in the impact of expansion between Black and White patients in the United States, and why insurance alone appears to be insufficient to overcome structural barriers to care for some populations.

Lung Cancer

Qinjin Fan, PhD, on Equitable Lung Cancer Care and Mortgage Discrimination

Qinjin Fan, PhD, of the American Cancer Society, explores the question of how mortgage discrimination is linked to lower rates of guideline-concordant care for patients with non–small cell lung cancer. This study highlights the critical need to understand the pathways through which mortgage denials may negatively affect the receipt of equitable care (Abstract 3).

Leukemia

Christopher E. Jensen, MD, on Older Adults With AML: A Price Paid for High-Intensity Chemotherapy?

Christopher E. Jensen, MD, of the University of North Carolina School of Medicine, talks about older adults with acute myeloid leukemia who receive high-intensity chemotherapy. Although they may live longer, much of their survival gains may be spent engaged in oncology care (Abstract 376).

Advertisement

Advertisement




Advertisement